for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Elanco Animal Health Inc

ELAN.N

Latest Trade

31.51USD

Change

-0.13(-0.41%)

Volume

514,319

Today's Range

30.67

 - 

31.65

52 Week Range

15.17

 - 

34.08

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
31.64
Open
31.60
Volume
514,319
3M AVG Volume
91.35
Today's High
31.65
Today's Low
30.67
52 Week High
34.08
52 Week Low
15.17
Shares Out (MIL)
471.92
Market Cap (MIL)
14,870.04
Forward P/E
71.97
Dividend (Yield %)
--

Next Event

Q4 2020 Elanco Animal Health Inc Earnings Release

Latest Developments

More

Elanco Begins Next Phase Of Integration Post-Bayer Animal Health Acquisition Executive Committee Member Sarena Lin To Depart

Elanco Animal Health Inc Says Increased And Tightened Q4 2020 Revenue Guidance To $1,040 To $1,070 Million

Elanco Animal Health Inc Launchs A Public Offering Of 54.5 Mln Shares Of Its Common Stock Held By Bayer World Investments B.V

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Elanco Animal Health Inc

Elanco Animal Health Incorporated is an animal health company that develops, manufactures and markets products for companion and food animals. The Company offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. It provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. It also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. It also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. It also provides products in poultry and aquaculture production.

Industry

Biotechnology & Drugs

Contact Info

2500 Innovation Way N

GREENFIELD, IN

46140-9163

United States

https://www.elanco.com/

Executive Leadership

R. David Hoover

Independent Chairman of the Board

Jeffrey N. Simmons

President, Chief Executive Officer, Director

Todd S. Young

Chief Financial Officer, Executive Vice President

Michael-Bryant Hicks

Executive Vice President, General Counsel, Corporate Secretary

David S. Kinard

Executive Vice President of Human Resources

Key Stats

2.56 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

3.1K

2019

3.1K

2020(E)

3.2K
EPS (USD)

2018

1.180

2019

1.060

2020(E)

0.438
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.09
Price To Book (MRQ)
1.78
Price To Cash Flow (TTM)
113.25
Total Debt To Equity (MRQ)
73.59
LT Debt To Equity (MRQ)
66.95
Return on Investment (TTM)
-2.11
Return on Equity (TTM)
-1.89

Latest News

Latest News

Sachem Head takes $1.2 billion position in Elanco, stock price surges

Hedge fund Sachem Head Capital Management said on Wednesday that it owns a $1.2 billion stake in Elanco Animal Health Inc and plans to push for changes at the company that makes medicines and vaccinations for pets and livestock.

Elanco to cut over 900 positions in first reorganization since Bayer unit deal

Elanco Animal Health Inc <ELAN.N> said on Wednesday it would cut more than 900 positions across nearly 40 countries, in the first restructuring action since the closing of its $6.89 billion acquisition of Bayer's <BAYGn.DE> veterinary drugs unit.

Elanco Animal Health to cut over 900 positions to lower costs

Elanco Animal Health Inc said on Wednesday it would cut more than 900 positions across nearly 40 countries, in the first restructuring action since the closing of its $6.89 billion buyout of Bayer's veterinary drugs unit.

Elanco's Brazil unit taps new executive as $6.89 billion Bayer deal concluded

Sérgio Schuler was appointed director general of Elanco Animal Health Inc's <ELAN.N> Brazil unit after the U.S.-based veterinary products firm completed its acquisition of Bayer's <BAYGn.DE> animal health division on Monday.

Elanco Animal Health wins approval to buy Bayer unit

Elanco Animal Health <ELAN.N> has won U.S. antitrust approval to buy Bayer AG's <BAYGn.DE> animal health business on condition that it sell assets to treat three ailments, two in dogs and one in cattle, the Federal Trade Commission said on Wednesday.

Elanco to divest brands, forgo Canadian rights for Bayer's unit deal

Elanco Animal Health Inc <ELAN.N> has decided against acquiring Bayer AG's Canadian distribution rights to several poultry insecticides, Canada's Competition Bureau said on Tuesday, as it looks to complete a $7.6-billion deal.

BRIEF-Elanco Animal -Entered Into Amendment No. 3 To Certain Share And Asset Purchase Agreement Dated As Of August 20

* ELANCO ANIMAL HEALTH- ENTERED INTO AMENDMENT NO. 3 TO CERTAIN SHARE AND ASSET PURCHASE AGREEMENT DATED AS OF AUGUST 20, 2019

BRIEF-Elanco Announces European Commission Approval Of Pending Acquisition Of Bayer Animal Health

* ELANCO ANNOUNCES EUROPEAN COMMISSION APPROVAL OF PENDING ACQUISITION OF BAYER ANIMAL HEALTH

Elanco wins conditional EU antitrust okay for $7.6 billion Bayer deal

Elanco Animal Health <ELAN.N> secured EU antitrust clearance on Monday to buy Bayer's <BAYGn.DE> veterinary drugs unit after pledging to sell some products to address competition concerns about the $7.6 billion deal.

BRIEF-Elanco Animal Health Reports Q1 Adjusted Earnings Per Share $0.13

* Q1 REVENUE $657.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $718.4 MILLION

BRIEF-Elanco Expands Executive Team To Lead Company Post Bayer Animal Health Acquisition

* ELANCO EXPANDS EXECUTIVE TEAM TO LEAD COMPANY POST BAYER ANIMAL HEALTH ACQUISITION

BRIEF-Elanco Animal Health Submits Form Co To European Commission

* ELANCO ANIMAL HEALTH SUBMITS FORM CO TO EUROPEAN COMMISSION

BRIEF-Elanco, Vetnow Collaborate To Expand Access To Veterinary Care

* ELANCO, VETNOW COLLABORATE TO EXPAND ACCESS TO VETERINARY CARE, RELIEVE IMPACT OF COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Elanco Animal Health Says CEO Jeffrey Simmons 2019 Total Compensation Was $15.8 Mln Versus $5.4 Mln In 2018

* ELANCO ANIMAL HEALTH SAYS CEO JEFFREY SIMMONS 2019 TOTAL COMPENSATION WAS $15.8 MILLION VERSUS $5.4 MILLION IN 2018 - SEC FILING

BRIEF-UK's CMA Invites Comments On Dechra Pharmaceuticals, Elanco Animal Health

* UK'S CMA INVITES COMMENTS ON ANTICIPATED ACQUISITION BY DECHRA PHARMACEUTICALS PLC OF OSURNIA BUSINESS OF ELANCO ANIMAL HEALTH INCORPORATED

BRIEF-Elanco Animal Health Withdraws Its Previously Announced 2020 Revenue And EPS Guidance

* ELANCO ANIMAL HEALTH INC - WITHDRAWING ITS PREVIOUSLY ANNOUNCED 2020 REVENUE AND EARNINGS PER SHARE GUIDANCE.

BRIEF-Elanco Signs Agreement With Merck Animal Health To Divest Worldwide Rights For Vecoxan

* PRESS RELEASE - ELANCO SIGNS AGREEMENT WITH MERCK ANIMAL HEALTH TO DIVEST WORLDWIDE RIGHTS FOR VECOXAN®

Elanco to become No.2 in animal health with $7.6 billion Bayer deal

Elanco Animal Health <ELAN.N> agreed to buy Bayer's <BAYGn.DE> veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion, creating the second largest maker of medicines for pets and livestock and expanding Elanco's reach online.

Elanco to buy Bayer's animal health unit for $7.6 billion

Elanco Animal Health Inc said on Tuesday it would buy Bayer AG's animal health unit in a cash and stock deal valued at $7.6 billion, a move that would create the second largest animal health business and expand Elanco's reach in the pet e-commerce space.

UPDATE 1-Bayer, Elanco aiming to reach animal-health deal next week - Bloomberg

Germany's Bayer AG and U.S. drug firm Elanco Animal Health Inc aim to reach an agreement to combine their pet-health businesses as soon as next week, Bloomberg reported https://www.bloomberg.com/news/articles/2019-08-07/elanco-bayer-said-aiming-to-reach-animal-health-deal-next-week...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up